Objective-To investigate the value of measuring maternal urea resistant neutrophil alkaline phosphatase activity as an antenatal screening test for Down's syndrome.
Introduction
Several substances are present at abnormally high or low concentrations in serum from pregnant women whose fetuses have-Down's syndrome. For three of them-a fetoprotein, unconjugated oestriol, and human chorionic gonadotrophin-the association is strong enough for their measurement to form the basis for antenatal screening for Down's syndrome in early pregnancy,' whereas for others such as pregnancy specific ,13 glycoprotein, progesterone, and dehydroepiandrosterone sulphate the association is weaker.24 In a study of four pregnant women whose fetuses had been diagnosed as having Down's syndrome three of the women had raised activities of urea resistant neutrophil alkaline phosphatase; in the fourth, who did not, the pregnancy ended in an intrauterine death. 5 This observation together with the finding that activity of urea resistant neutrophil alkaline phosphatase was, on average, raised in 33 women who in the past had had a pregnancy in which the fetus had Down's syndrome6 prompted us to investigate whether measurement of this activity might be a useful antenatal screening test for fetal Down's syndrome.
Patients and methods
During 1987-9 the department of environmental and preventive medicine at St Bartholomew's Hospital was notified whenever Down's syndrome was diagnosed antenatally in any of the eight cytogenetics laboratories in the four Thames regional health authorities. The study was restricted to singleton pregnancies. With the agreement of the consultants concerned we contacted the women in whom the diagnosis had been made (the index patients) and invited them to provide a blood sample. All 72 who were invited agreed; Down's syndrome had been diagnosed after amniocentesis in 70 and after chorionic villus sampling in two. The blood sample was collected at a median of 19 weeks of pregnancy, before a therapeutic abortion; a blood film was made immediately.
Forty six women with singleton pregnancies in which the fetus did not have Down's syndrome (controls) were identified in the same way as the index patients (after amniocentesis in 45 and after chorionic villus sampling in one) after confirmation that the fetus had a normal karyotype. The blood samples were collected at a median of 21 weeks of pregnancy. This was later than in the index patients because the interval between amniocentesis (or chorionic villus sampling) and the collection of blood for measurement of the enzyme activity was longer in the controls: the cytogenetics laboratories usually reported aneuploidy straight away but reported a normal karyotype only after less severe chromosomal changes had been excluded. To obtain more controls at an earlier stage of pregnancy so that enzyme activities in the index patients could be compared with those in controls whose pregnancy was of the same duration we identified 110 women with singleton pregnancies attending their first routine antenatal clinic at the John Radcliffe Maternity Hospital, Oxford, who provided blood samples.
Blood for this in the analysis the average difference in score between them (55) was added to the lower scorer's results. As the scores increase with advancing pregnancy in early pregnancy they were expressed as multiples of the expected (normal) median for the control patients whose pregnancy was of the same duration. The expected medians were obtained by linear regression of the observed control median values for each week of pregnancy on the median duration of pregnancy in days, weighted by the number ofwomen at each week. Duration of pregnancy was measured from the first day of the last menstrual period. syndrome was 79% (95% confidence interval 70 to 89%). Table II shows the median and 25th and 75th centiles of urea resistant neutrophil alkaline phosphatase activity in the index and control patients according to maternal age, the indication for amniocentesis (or chorionic villus sampling), and the time between that procedure and measurement of the enzyme activity. There was no obvious association between the enzyme activity and any of these three variables.
Discussion
We confirmed the observations of Grozdea et al that blood urea resistant neutrophil alkaline phosphatase activity is raised in pregnant women whose fetus has Down's syndrome5; we found that the median activity was 1 65 times that in women whose fetuses did not have the syndrome. When a cut off value of 1-40 multiples of the normal median was used 79% of the index patients were identified with a rate of false positive results of 5%. At present the single most effective marker for Down's syndrome is human chorionic gonadotrophin concentration, which detects 37% of women whose fetuses have the syndrome at a cut off that yields a 5% false positive rate (derived from gaussian distributions with the parameters reported previously'). Measurement of urea resistant neutrophil alkaline phosphatase activity is therefore a more discriminating test. To our knowledge no other single blood test can identify Down's syndrome so effectively.
We do not know why the activity of urea resistant neutrophil alkaline phosphatase is raised in pregnant women whose fetuses have Down's syndrome, although it may be related to the observation that this activity is raised in people with Down's syndrome.8 The enzyme activity is also raised in women who in the past have had a pregnancy in which the fetus had Down's syndrome,6 an observation that cannot be readily explained by a direct fetal effect unless the fetus provides a signal to the mothers' neutrophils or a neutrophil precursor that persists after the pregnancy.
Our results were not influenced to any great extent by the fact that most samples were collected after amniocentesis or chorionic villus sampling as in the controls the medians were similar in the women who did (1 05 multiples of the normal median) and did not (1 00 multiples of the normal median) have either procedure (table II) 
We are especially grateful to the patients who agreed to be included in the study and the late Professor Sir Alec Turnbull and other obstetricians who approached patients on our behalf and agreed to our interviewing them. 
Patients, methods, and results
We studied elderly psychiatric patients living in the area covered by Camberwell Health Authority, London. Altogether 180 were enrolled in the study, of whom 86 had died by three years. Necropsy was performed on 54 patients, and we report here on the first 50.
The clinical criteria used were those of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association.' Probable Alzheimer's disease was diagnosed in patients with a history of a slowly progressive dementia without concomitant physical illness. Possible Alzheimer's disease was diagnosed in patients with atypical features of the disease or physical illness. Definite Alzheimer's disease was diagnosed only when the disease was confirmed by histopathological examination-that is, by the finding of widespread neocortical and hippocampal disease with plaques or neurofibrillary tangles, or both. Diffuse Lewy body disease was diagnosed when Lewy bodies were found not only in the substantia nigra and locus coeruleus but also in the cortex, particularly in the parahippocampal gyrus. Vascular damage was considered to be important when multiple, widespread macroscopic or microscopic lesions were identified.
The average age of the 50 patients studied was 82-3 years (range 70-99). The table shows 
